select a format

Single User License
USD 1500 INR 97530
Site License
USD 3000 INR 195060
Corporate User License
USD 4500 INR 292590

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Eisai Co., Ltd-Product Pipeline Review-2015

Eisai Co., Ltd-Product Pipeline Review-2015


  • Products Id :- GMDHC07692CDB
  • |
  • Pages: 184
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Eisai Co., Ltd-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Eisai Co., Ltd-Product Pipeline Review-2015', provides an overview of the Eisai Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Eisai Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Eisai Co., Ltd. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Eisai Co., Ltd.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Eisai Co., Ltd.'s pipeline products

Reasons To Buy

Evaluate Eisai Co., Ltd.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Eisai Co., Ltd. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Eisai Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Eisai Co., Ltd. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Eisai Co., Ltd.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Eisai Co., Ltd. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Eisai Co., Ltd. Snapshot 6

Eisai Co., Ltd. Overview 6

Key Information 6

Key Facts 6

Eisai Co., Ltd-Research and Development Overview 7

Key Therapeutic Areas 7

Eisai Co., Ltd-Pipeline Review 14

Pipeline Products by Stage of Development 14

Pipeline Products-Monotherapy 15

Pipeline Products-Combination Treatment Modalities 16

Pipeline Products-Partnered Products 17

Pipeline Products-Out-Licensed Products 19

Eisai Co., Ltd-Pipeline Products Glance 21

Eisai Co., Ltd-Late Stage Pipeline Products 21

Eisai Co., Ltd-Clinical Stage Pipeline Products 24

Eisai Co., Ltd-Early Stage Pipeline Products 28

Eisai Co., Ltd-Drug Profiles 30

cinitapride 30

eribulin mesylate 31

lenvatinib 36

lorcaserin hydrochloride 42

mecobalamin 45

mitiglinide 46

perampanel 48

clevudine 51

donepezil hydrochloride Patch 53

(diclofenac sodium + eperisone) 55

avatrombopag 56

BAN-2401 58

decitabine 60

denileukin diftitox 63

donepezil hydrochloride 65

E-2609 66

E-3710 67

E-6005 68

E-7820 69

eritoran tetrasodium 70

fosravuconazole 72

indisulam 74

irofulven 76

lemborexant 79

rabeprazole sodium DR 80

Vaccine for Metastatic Melanoma 82

bexarotene 83

E-6011 85

E-6201 86

E-7449 88

golvatinib + lenvatinib 89

golvatinib tartrate 91

tazemetostat 93

E-2027 95

E-6007 96

E-7046 97

E-7090 98

E-7389LF 99

AT-791 100

E-1210 101

E-2072 102

E-2508 103

E-5539 104

E-6446 105

ER-358063 106

ER-409903 107

ER-410660 108

ER-417258 109

ER-886046 110

ER-901356 111

Monoclonal Antibody to Inhibit CCL20 for Arthritis and Contact Hypersensitivity 112

SJ-733 113

Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders 114

Small Molecule to Inhibit Cytidine Deaminase for Cancer 115

Small Molecule to Inhibit GWT1 Protein for Malaria 116

Small Molecules for Bacterial Infections 117

Small Molecules for Chagas Disease 118

Small Molecules for Lymphatic Filariasis and Onchocerciasis 119

Small Molecules for Malaria 120

Small Molecules for Oncology 121

Small Molecules for Tuberculosis 122

TRI-4 123

Eisai Co., Ltd-Pipeline Analysis 124

Eisai Co., Ltd-Pipeline Products by Target 124

Eisai Co., Ltd-Pipeline Products by Route of Administration 128

Eisai Co., Ltd-Pipeline Products by Molecule Type 129

Eisai Co., Ltd-Pipeline Products by Mechanism of Action 130

Eisai Co., Ltd-Recent Pipeline Updates 133

Eisai Co., Ltd-Dormant Projects 168

Eisai Co., Ltd-Discontinued Pipeline Products 170

Discontinued Pipeline Product Profiles 170

Eisai Co., Ltd-Company Statement 173

Eisai Co., Ltd-Locations And Subsidiaries 174

Head Office 174

Other Locations & Subsidiaries 174

Appendix 178

Methodology 178

Coverage 178

Secondary Research 178

Primary Research 178

Expert Panel Validation 178

Contact Us 178

Disclaimer 179

List of Tables

Eisai Co., Ltd., Key Information 11

Eisai Co., Ltd., Key Facts 11

Eisai Co., Ltd-Pipeline by Indication, 2015 13

Eisai Co., Ltd-Pipeline by Stage of Development, 2015 19

Eisai Co., Ltd-Monotherapy Products in Pipeline, 2015 20

Eisai Co., Ltd-Combination Treatment Modalities in Pipeline, 2015 21

Eisai Co., Ltd-Partnered Products in Pipeline, 2015 22

Eisai Co., Ltd-Partnered Products/ Combination Treatment Modalities, 2015 23

Eisai Co., Ltd-Out-Licensed Products in Pipeline, 2015 24

Eisai Co., Ltd-Out-Licensed Products/ Combination Treatment Modalities, 2015 25

Eisai Co., Ltd-Pre-Registration, 2015 26

Eisai Co., Ltd-Filing rejected/Withdrawn, 2015 27

Eisai Co., Ltd-Phase III, 2015 28

Eisai Co., Ltd-Phase II, 2015 29

Eisai Co., Ltd-Phase I, 2015 31

Eisai Co., Ltd-Preclinical, 2015 33

Eisai Co., Ltd-Discovery, 2015 34

Eisai Co., Ltd-Pipeline by Target, 2015 129

Eisai Co., Ltd-Pipeline by Route of Administration, 2015 133

Eisai Co., Ltd-Pipeline by Molecule Type, 2015 134

Eisai Co., Ltd-Pipeline Products by Mechanism of Action, 2015 135

Eisai Co., Ltd-Recent Pipeline Updates, 2015 138

Eisai Co., Ltd-Dormant Developmental Projects,2015 173

Eisai Co., Ltd-Discontinued Pipeline Products, 2015 175

Eisai Co., Ltd., Subsidiaries 179

List of Figures

Eisai Co., Ltd-Pipeline by Top 10 Indication, 2015 13

Eisai Co., Ltd-Pipeline by Stage of Development, 2015 19

Eisai Co., Ltd-Monotherapy Products in Pipeline, 2015 20

Eisai Co., Ltd-Combination Treatment Modalities in Pipeline, 2015 21

Eisai Co., Ltd-Partnered Products in Pipeline, 2015 22

Eisai Co., Ltd-Out-Licensed Products in Pipeline, 2015 24

Eisai Co., Ltd-Pipeline by Top 10 Target, 2015 129

Eisai Co., Ltd-Pipeline by Top 10 Route of Administration, 2015 133

Eisai Co., Ltd-Pipeline by Top 10 Molecule Type, 2015 134

Eisai Co., Ltd-Pipeline Products by Top 10 Mechanism of Action, 2015 135

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Eisai Co., Ltd.; Eisai Co., Ltd-Key Therapeutics; Eisai Co., Ltd-Pipeline Overview and Promising Molecules; Eisai Co., Ltd-News; Eisai Co., Ltd-Latest Updates; Eisai Co., Ltd-Pipeline; Eisai Co., Ltd-Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com